UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2018
(Commission File No. 001-38475)
ASLAN PHARMACEUTICALS LIMITED
(REG. NO. 289175)
(Translation of registrant’s name into English)
CAYMAN ISLANDS
(Jurisdiction of incorporation or organisation)
83 CLEMENCEAU AVENUE
#12-03 UE SQUARE
SINGAPORE 239920
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (1):
Yes ☐ No ☒
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101 (b) (7):
Yes ☐ No ☒
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.
|
|
|
|
ASLAN PHARMACEUTICALS LIMITED |
|
|
(Registrant) |
|
|
|
|
|
By: |
/s/ Ben Goodger
|
|
Name: |
Ben Goodger |
|
Title: |
General Counsel |
Date: December 06, 2018
Subject: Announcement on receiving the Financial Supervisory Commission of Taiwan (“FSC”) approval for issuing ordinary shares for sponsoring the issuance of American Depository Receipts
Date of events: 12/05/2018
Contents:
1. Date of occurrence of the event: 12/05/2018
2. Company name: ASLAN Pharmaceuticals Limited
3. Relationship to the Company (please enter "head office" or" subsidiaries"): Head office
4. Reciprocal shareholding ratios: NA
5. Cause of occurrence: Received the approval letter No.1070344286 from FSC for issuing ordinary shares for sponsoring the issuance of American Depository Receipts.
6. Countermeasures: To proceed the issuance of ordinary shares for sponsoring the issuance of American Depository Receipts as per the aforesaid approval letter.
7. Any other matters that need to be specified: None.